Anne Louise Kjølbye

Author

Anne Louise Kjølbye

Zealand Pharma (Denmark)

Also Known As

ANNE LOUISE KJØLBYE, Anne Kjølbye, Anne Louise Kjolbye, Anne Louise Kjølbye

Publications

1.3K

Citations

H-Index

Concepts

All Affiliations

Zealand Pharma (Denmark)University of Copenhagen University of Pittsburgh Berry & Associates (United States)St. Paul's Hospital

About

Anne Louise Kjølbye is an author at Zealand Pharma (Denmark) specializing in medicine, physiology, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	409
2	Health Sciences	2	2	93
3	Biochemistry	2	2	197
4	Natural Sciences	1	1	64
5	Anesthesia	1	1	27

Anne Louise Kjølbye

Publications

1.1K

Citations

H-Index

Page 1

	Year	Citations
ZP123 Increases Gap Junctional Conductance and Prevents Reentrant Ventricular Tachycardia During Myocardial Ischemia in Open Chest Dogs Dezhi Xing, Anne Louise Kjølbye, Morten Schak Nielsen, Journal of Cardiovascular Electrophysiology	2003	135
Effect of Selepressin vs Placebo on Ventilator- and Vasopressor-Free Days in Patients With Septic Shock Pierre‐François Laterre, Scott Berry, Allan Blemings, JAMA	2019	134
Identification of ischemia-regulated phosphorylation sites in connexin43: A possible target for the antiarrhythmic peptide analogue rotigaptide (ZP123) Lene Nygaard Axelsen, Martin Stahlhut, Shabaz Mohammed, Journal of Molecular and Cellular Cardiology Signal TransductionBiochemistryG Protein-coupled ReceptorMedicinePossible Target	2006	133
Selepressin, a novel selective vasopressin V1A agonist, is an effective substitute for norepinephrine in a phase IIa randomized, placebo-controlled trial in septic shock patients James A. Russell, Jean‐Louis Vincent, Anne Louise Kjølbye, Critical Care	2017	103
Differential Extracellular Signal‐Regulated Kinases 1 and 2 Activation by the Angiotensin Type 1 Receptor Supports Distinct Phenotypes of Cardiac Myocytes Mark Aplin, Gitte Lund Christensen, Mikael Schneider, Basic & Clinical Pharmacology & Toxicology Cardiac MuscleMyocyte HypertrophyCardiovascular FunctionCellular PhysiologyAngiotensin Type 1	2007	77
Cardiac and metabolic changes in long-term high fructose-fat fed rats with severe obesity and extensive intramyocardial lipid accumulation Lene Nygaard Axelsen, Jacob B. Lademann, Jørgen S. Petersen, American Journal of Physiology-Regulatory, Integrative and Comparative Physiology ObesityMetabolic SyndromeDrinking WaterMetabolic DisorderMedicine	2010	75
A Selective V1A Receptor Agonist, Selepressin, Is Superior to Arginine Vasopressin and to Norepinephrine in Ovine Septic Shock* Xinrong He, Fuhong Su, Fabio Silvio Taccone, Critical Care Medicine	2015	75
Pharmacological Characterization of the New Stable Antiarrhythmic Peptide Analog Ac-d-Tyr-d-Pro-d-Hyp-Gly-d-Ala-Gly-NH2 (ZP123): In Vivo and in Vitro Studies Anne Louise Kjølbye, Carsten Knudsen, Trine Jepsen, Journal of Pharmacology and Experimental Therapeutics	2003	71
The Angiotensin Type 1 Receptor Activates Extracellular Signal‐Regulated Kinases 1 and 2 by G Protein‐Dependent and ‐Independent Pathways in Cardiac Myocytes and Langendorff‐Perfused Hearts Mark Aplin, Gitte Lund Christensen, Mikael Schneider, Basic & Clinical Pharmacology & Toxicology	2007	65
Acetylcholinesterase and butyrylcholinesterase inhibitory compounds from Corydalis cava Schweigg. & Kort Anne Adsersen, Anne Louise Kjølbye, Ole Leinikka Dall, Journal of Ethnopharmacology Molecular PharmacologyMedicinal ChemistryInhibitory ActivityBiochemistryNatural Sciences	2007	64

Page 1